Terkko Navigator / -/ Feeds / " ( ( Veren kolesterolia alentavat lääkkeet )|( Kolesterolilääkkeet )|( Kolesterolia al"

Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women

Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study

Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy.

Cholesterol absorption: influence of body weight and the role of plant sterols.

Cholesterol-lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.

Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics

Tampereen tutkimus antaa toivoa sairastuneille– Tietyt verenpaine- ja kolesterolilääkkeet saattavat ehkäistä syöpäkuolemia

Tampereen tutkimus antaa toivoa sairastuneille– Tietyt verenpaine- ja kolesterolilääkkeet saattavat ehkäistä syöpäkuolemia

PCSK9 inhibitors for prevention of cardiovascular disease

Quantitative Tyr Phosphoproteomic Analyses Identify Cholesterol as a Master Regulator of Tumor Adaptive Resistance to MAPK Inhibition

Drug-induced effects on cholesterol catabolism and bile acids.

Drug-induced effects on cholesterol catabolism and bile acids.

De novo cholesterol biosynthesis and its trafficking in LAMP-1 positive vesicles are involved in replication and spread of Marek's disease virus.

Novel cholesterol-dependent regulation of cardiac KATP subunit expression revealed using histone deacetylase inhibitors.

Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms.

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms.

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms.

4CPS-020 Use, efficacy and adherence to treatment with PCKS9 inhibitors in real clinical practice

Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis

Kolesterolilääke aiheuttaa nivelkipuja - mistä apua?

Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention

Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.

SREBP-1c Gene Polymorphism is Associated with Increased Inhibition of Cholesterol-Absorption in Response to Ezetimibe Treatment.

SREBP-1c Gene Polymorphism is Associated with Increased Inhibition of Cholesterol-Absorption in Response to Ezetimibe Treatment.

Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17-beta estradiol fatty acyl esters.

Dietary cholesterol is essential to mast cell activation and associated obesity and diabetes in mice.

Amiodarone disrupts cholesterol biosynthesis pathway and causes accumulation of circulating desmosterol by inhibiting 24-dehydro-cholesterol reductase.

Amiodarone disrupts cholesterol biosynthesis pathway and causes accumulation of circulating desmosterol by inhibiting 24-dehydro-cholesterol reductase.

Amiodarone disrupts cholesterol biosynthesis pathway and causes accumulation of circulating desmosterol by inhibiting 24-dehydro-cholesterol reductase.

4CPS-022 PCSK9 inhibitors: evaluation of effectiveness in our centre in relation to the official clinical endpoints

5PSQ-017 PCSK-9 inhibitors: real world effectiveness

6ER-001 PCSK9 inhibitors: variation in the lipid profile in a real world setting

Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study

The Degron Architecture of Squalene Monooxygenase and How Specific Lipids Calibrate Levels of This Key Cholesterol Synthesis Enzyme.

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV

Amiodarone disrupts cholesterol biosynthesis pathway and causes accumulation of circulating desmosterol by inhibiting 24-dehydrocholesterol reductase

The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis [Research Articles]

Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women.

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?

Kolesterolilääkkeet voivat suojata sydän- ja verisuonitaudeilta – syö näin, jos kolesterolisi on koholla

5PSQ-177 Cardiovascular risk and altered lipid profile associated with treatment with the kinase JAK inhibitors, tofacitinib and baricitinib

Bisphosphonate inhibitors of squalene synthase protect cells against cholesterol-dependent cytolysins

JCM, Vol. 10, Pages 3456: Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

Population Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program

Nutrients, Vol. 13, Pages 3156: Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells

Evaluating Targeted Therapies in Ovarian Cancer Metabolism : Novel Role for PCSK9 and Second Generation mTOR Inhibitors

IJMS, Vol. 22, Pages 12198: A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study